MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

112.26 3.78

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

108.09

Max

114.54

Pagrindiniai rodikliai

By Trading Economics

Pajamos

15M

-59M

Pardavimai

2.7M

121M

Pelno marža

-48.914

Darbuotojai

712

EBITDA

14M

-57M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+63.57% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-179M

5.3B

Ankstesnė atidarymo kaina

108.48

Ankstesnė uždarymo kaina

112.26

Naujienos nuotaikos

By Acuity

7%

93%

4 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-09 15:46; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250 Million Private Placement

2025-07-09 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 20:26; UTC

Uždarbis

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025-07-09 19:18; UTC

Rinkos pokalbiai

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025-07-09 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025-07-09 18:31; UTC

Rinkos pokalbiai

Some Fed Officials Supported Considering July Cut -- Market Talk

2025-07-09 17:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk -2-

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025-07-09 16:14; UTC

Įsigijimai, susijungimai, perėmimai

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025-07-09 16:12; UTC

Rinkos pokalbiai

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025-07-09 16:08; UTC

Rinkos pokalbiai

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025-07-09 15:31; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250M Private Placement

2025-07-09 15:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025-07-09 15:27; UTC

Rinkos pokalbiai

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025-07-09 14:36; UTC

Įsigijimai, susijungimai, perėmimai

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025-07-09 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025-07-09 14:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-09 14:26; UTC

Rinkos pokalbiai

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

63.57% į viršų

12 mėnesių prognozė

Vidutinis 177.33 USD  63.57%

Aukščiausias 210 USD

Žemiausias 148 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

15

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

4 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.